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Abstract
Background: Clinical swollen joint examination of the obese rheumatoid arthritis (RA) patient can be difficult.
Musculoskeletal Ultrasound (MSUS) has higher sensitivity than physical examination for swollen joints (SJ). The
purpose of this study was to determine the joint-specific association between power Doppler (PDUS) and
clinical SJ in RA across body mass index (BMI) categories.
Methods: Cross-sectional clinical and laboratory data were collected on 43 RA patients. PDUS was performed on 9
joints (wrist, metacarpalphalangeal 2–5, proximal interphalgeal 2/3 and metatarsalphalangeal 2/5). DAS28 and clinical
disease activity index (CDAI) were calculated. Patients were categorized by BMI: <25, 25–30, and >30. Demographic
and clinical characteristics were compared across BMI groups with Kruskal-Wallis test and chi-square tests. Joint-level
associations between PDUS and clinically SJ were evaluated with mixed effects logistic regression models.
Results: While demographics and clinically-determined disease activity were similar among BMI groups, PDUS scores
significantly differed (p = 0.02). Using PDUS activity as the reference standard for synovitis and clinically SJ as the test,
the positive predictive value of SJ was significantly lower in higher BMI groups (0.71 in BMI < 25, 0.58 in BMI
25–30 and 0.44 in BMI < 30) (p = 0.02). The logistic model demonstrated that increased BMI category resulted
in decreased likelihood of PDUS positivity (OR 0.52, p = 0.03).
Conclusions: This study suggests that in an obese RA patient, a clinically assessed SJ is less likely to represent
true synovitis (as measured by PDUS). Disease activity in obese RA patients may be overestimated by CDAI/
DAS28 calculations and clinicians when considering change in therapy.
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Background
Musculoskeletal ultrasound (MSUS) with power Doppler
(PDUS) has become an accepted modality to identify
features of inflammatory arthritis including synovitis and
enthesitis and expert panels from the American College
of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) consider its use reasonable
for monitoring disease activity in patients with rheumatoid
arthritis (RA) [1, 2]. Synovitis is the manifestation of
synovial proliferation and angiogenesis, which is an early
pathologic change leading to bony destruction by locally
invading the synovium-cartilage interface [3]. The Outcome
Measures in Rheumatoid Arthritis Clinical Trials (OMER-
ACT) initiative defines synovitis by PDUS as abnormal
hypoechoic intraarticular tissue that is non-displaceable,
poorly compressible, and exhibiting Doppler signal [4].
Unlike healthy synovium, inflamed synovium is hyperemic
and can be semi quantitatively graded, most commonly on
a 4-point scale of 0 to 3 for PDUS activity [5]. Multiple
studies measuring PDUS have documented improvement
of PDUS scores in response to RA treatments [6, 7]. PDUS
is reported to have higher sensitivity and be more reliable
for synovitis evaluation than an examination of swollen
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joints [8] and is predictive of relapse and radiographic
disease progression [9].
While the uses and benefits of MSUS in RA are
becoming widely recognized, the burden of time and
cost can be prohibitive in obtaining MSUS on every
RA patient within the rheumatologists’ clinical prac-
tice. It may be beneficial to better define the type of
RA patient and clinical scenario in which MSUS will
have differential impact on therapeutic management
especially given the push towards early and aggressive
control of disease activity. The majority of RA patients
in the United States are considered overweight or
obese [10, 11], and these patients have a poorer quality
of life [12] and are less likely to attain remission by
Disease Activity Score (DAS28) <2.6 despite treatment
as compared to non-obese RA patients [13, 14]. This
lack of measured response in obese RA patient could
be due to a differential response to therapy, a measure-
ment error in assessing disease activity, or a combination
of both. PDUS in the obese RA patient has not been fully
described in the literature to date.
Our objective in this study was to evaluate the joint
specific association between synovitis measured by




Patients meeting the ACR 1987 and ACR/EULAR RA
diagnostic criteria [15, 16] and whose treating physicians
were considering switching and/or escalating immuno-
suppressive therapy were recruited from University of
California at Los Angeles (UCLA) rheumatology clinics.
Patients were required to have active RA, with a minimal
swollen joint count (SJC) ≥ 2 and tender joint count (TJC) ≥
2 of the 28 joint count examined. Eligible RA patients met
the following criteria: age ≥ 18, stable disease modifying
anti-rheumatic drugs (DMARDs), and on prednisone ≤
10 mg for at least one month. Patients were excluded if
they were pregnant or breast feeding, or if they had arthro-
plasty of the joints examined by ultrasound. Based on these
inclusion/exclusion criteria, 43 patients were evaluated.
These patients were then divided into three groups based
on their body mass index (BMI): <25, 25 to 30, and >30 for
analysis. The study was approved by the UCLA institutional
review board (IRB#11-001225-CR-00005).
Clinical study measures
Patients completed demographic questionnaires, and the
components of the DAS28 and Clinical Disease Activity
Index (CDAI) were obtained the same day as the ultra-
sound. The erythrocyte sedimentation rate (ESR) was
measured to calculate the DAS28/ESR. Rheumatoid
factor (RF) and anti-cyclic citrullinated protein antibody
(ACPA) were obtained for each patient. The total tender
and swollen joint count was assessed by a single study
investigator (VKR) prior to ultrasound.
Musculoskeletal ultrasound synovitis measures
MSUS assessment of PDUS and grey scale (GSUS)
hypertrophy and effusion was performed at the one-
time visit. The sonographer (ABA) was an experienced
rheumatologist trained in MSUS and certified in
Rheumatology MSUS (rhMSUS). Images were ob-
tained using a GE Logic E9 machine with ML6-15
linear probe and the following presets: red-yellow
color map, Doppler frequency 10.0 MHz, PRF 0.8KHz,
and gain adjusted just below noise. Based on a prior
publication by Backhaus et al [6], with the addition of
2 joints (metacarpalphalangeal 4 and 5), a total of 9
joints were scanned by MSUS on the most active side:
wrist (dorsal longitudinal midline view), metacarpal-
phalangeal (MCP) joints 2, 3, 4, and 5 (dorsal/palmar
long views), proximal interphalgeal (PIP) joints 2 and
3 (dorsal/palmar long views) and metatarsalphalangeal
joints 2 and 5 (dorsal long view). PDUS and GSUS
were scored semi-quantitatively on a scale of 0–3 per
prior published consensus definitions [6]. Specifically,
PDUS was scored by the amount of power Doppler
signal in the intraarticular area: grade 0 = no color
signal, grade 1 = up to 3 color signals or 2 single and 1
confluent signal, grade 2 = greater than grade 1 to < 50%
color signal, and grade 3 = >50% color signal [6]. The max
score of the views obtained for each joint was computed
and then was theses maximums were summed across all 9
joints to obtain total PDUS (range 0–27) and GSUS (range
0–27) scores. An individual joint was considered to be
positive for synovitis if its max PDUS score was ≥1. The
clinical assessor was blinded to the ultrasound data, and
the ultrasonographer was blinded to the clinical assess-
ments. Additionally, when scoring the archived images, the
ultrasonographer was blinded to all clinical data. Once all
scans were completed the ultrasonographer re-read 10% of
randomly selected ultrasound visits for kappa intra-rater re-
liability calculations for GSUS and PDUS [17].
Statistical analysis
Patients’ mean (standard deviation [SD]) age and disease
duration were calculated for each BMI group and com-
pared across groups with t-tests. The proportion of female
and sero-positive (RF+ or ACPA+) patients was calculated
for each BMI group and compared across groups with
Fisher Exact Tests. The GSUS, PDUS, SJC, TJC, DAS28/
ESR-4, CDAI, and ESR for each BMI group were
compared across BMI groups with Kruskal-Wallis tests.
Kruskal-Wallis Tests were used for these US and clinical
measures because they exhibited skewed distributions in
visual assessments.
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Agreement between clinical swollen joint assessments
and PDUS assessments were evaluated for the full
cohort and each BMI group in several ways. First, the
overall percent of joints that were considered swollen
and PDUS positive were calculated for the full cohort
and each BMI group. Next, the percent of joint-specific
pairwise agreement between swollen joint assessment
and PDUS assessment was calculated. To assess the pre-
dictive relationship of clinical swollen joints versus PDUS
positivity (reference standard), the sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) of swollen joint assessment were calculated.
We constructed a mixed effects logistic regression model
to evaluate the correlates of PDUS positivity, as well as for
GSUS. This model included terms for SJC, BMI group (rep-
resented ordinally), age, sex, joint, as well as a random
effect for subject to account for the clustering of joints
within subjects. Within the logistic regression, BMI was
represented as an ordinal variable by converting the 3
categories of BMI as follows: BMI <25 = 1, BMI 25–30 = 2,
and BMI > 30 = 3. To evaluate the predictive ability of this
model for PDUS positivity, we constructed a ROC curve
using the predicted probabilities from the model and com-
puted the area under the ROC curve (AUC). Lastly, we
included a term in the model for specific joint to evaluate
in which joints the differences between BMI groups were
most pronounced.
Results
Demographic characteristics were similar among BMI
groups. The overall cohort was 86% female and 66%
ACPA or RF seropositive with a mean age of 52.1 (SD
12.9) and disease duration of 7.3 (SD 7.8) years (Table 1).
Within the cohort 93% of patients were on a DMARD,
19% were on Biologics, and 16% of patients were on
prednisone. There were no significant differences in
these characteristics across the BMI categories.
The overall median and interquartile ranges (IQR): 4 (2)
for SJC, 4 (4) for TJC, 6.3 (1.5) for DAS28/ESR-4, and 36.5
(29.0) CDAI score (Table 2). These disease activity as
measures were not significantly different across the BMI
groups. While GSUS was not significantly different across
BMI groups (p = 0.42), the PDUS scores significantly
differed across BMI groups with median (IQR) scores of 3
(3) for BMI group <25, 1 (3.5) for BMI group 25–30 and 0
(2) BMI group >30 (p = 0.02).
The prevalence of PDUS positive joints decreased
across BMI categories (54% for BMI < 25, 40% for BMI
25–30, and 30% for BMI > 30), while prevalence of swollen
joints in the high BMI group was only 3 percentage points
lower than in the low BMI group (48% for BMI < 25 vs
45% for BMI > 30) (Table 3). Using PDUS activity as the
reference standard for synovitis and SJC as the test (joint-
specific analyses), the positive predictive value (PPV) of
SJC was significantly lower in higher BMI groups (0.71 in
BMI < 25, 0.58 in BMI 25–30 and 0.44 in BMI > 30,
p = 0.02). The negative predicative value (NPV)
trended higher in >30 BMI group (0.62 for BMI group <25,
0.71 for BMI group 25–30, 0.81 in BMI group >30)
although was not statistically significant. In addition, clinic-
ally swollen joints had higher rates of PDUS compared to
non-swollen joints, and there was a decreasing trend of
PDUS positivity with increasing BMI for both swollen
and non-swollen joints (Fig. 1). For example, a clinically
swollen joint in a RA patient with normal BMI had 71%
chance of PDUS positivity, whereas a swollen joint in an
obese patient had a 44% chance. On the other hand, a
non-swollen joint in a normal BMI patient still had a
PDUS positivity rate of 38%, while lower in the obese
patient’s non-swollen joint (19%).
The logistic regression model demonstrates that each
BMI category increase is independently associated with
lower odds of PDUS positivity with an odds ratio of 0.52
(95% CI: 0.08, 0.88, p = 0.03), adjusting for covariates
(Table 4). Additionally, the logistic model shows that the
presence of clinical joint swelling is positively associated
with the likelihood of PDUS positivity (OR = 2.5, 95% CI:
1.4 to 4.5, p = 0.01). The AUC of the logistic model was
Table 1 Baseline demographics, mean (SD) or number (%)
Overall BMI <25 BMI 25–30 BMI >30 P-value
N = 43 N = 17 N = 12 N = 14
BMI1,* 28.9 (9.0) 21.3 (2.3) 27.2 (1.4) 39.5 (7.3)
Age (years)* 52.1 (12.9) 49.9 (16.9) 56.6 (7.5) 51.1 (10.5) 0.37
Disease duration (years)* 7.3 (7.8) 7.4 (9.6) 4.0 (3.8) 10.1 (7.2) 0.14
Female** 37 (86%) 17 (100%) 8 (67%) 12 (86%) 0.02
RF2 or CCP3 Positive** 27 (66%) 11 (69%) 9 (75%) 7 (54%) 0.55
DMARD (Y) 40 (93%) 1 (6%) 0 (0%) 2 (14%) 0.48
Biologics (Y) 8 (19%) 2 (12%) 2 (17%) 4 (28%) 0.55
Prednisone (Y) 7 (16%) 3 (18%) 2 (17%) 2 (14%) 0.99
1Body Mass Index, 2Rheumatoid Factor, 3Cyclic citrullinated peptide, *Mean (SD) and one-way ANOVA, **N (%) and Fisher Exact Test
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0.76 suggesting the combination of BMI, clinical swollen
joint assessment, sex and age provide strongly predict
the presence of PDUS positivity. Additionally, we con-
structed a similar logistic model for outcome of GSUS
positivity and found similar results for the association of
clinical swelling and GSUS (OR = 2.52) to what was
observed in the PDUS model (Table in Additional file 1).
In particular, the wrist, MCP2, and MCP3 had signifi-
cantly less PDUS positivity in the BMI > 30 group as
compared to the BMI < 25 group (Fig. 2). The ultraso-
nographer’s intra-rater reliability for GSUS and PDUS
was a kappa of 0.62 and 0.82, respectively.
Discussion
Despite continuing advances in therapeutic options for
RA, almost 30% of all RA patients will fail to meet the
goals of quick and sustained control of disease activity
with a first exposure to a biologic agent and will need to
switch therapy [18]. Given the emphasis on early inter-
vention to prevent the destructive changes in RA and
the push to “treat to target” (T2T) by national and inter-
national guidelines [19–21], there is incentive to know
when a patient is not responding to a given treatment.
The current gold standard for monitoring disease ac-
tivity and thus the “target” of T2T is usually DAS28
remission (<2.6) or low activity (<3.2). While the
majority of T2T studies and guidelines employ DAS28,
CDAI, or Simple Disease Activity Index (SDAI), there are
criticisms that these targets require prior blood work
(DAS28, SDAI), do not account for the joints in the feet,
and that the tender joint counts can be misleading for
disease activity measures due to attribution error in
patients with co-morbidities such as fibromyalgia and
osteoarthritis. Our study addresses the latter point. Other
studies have suggested that RA patients with fibromyalgia
were found to have elevated disease activity scores, how-
ever noted to have low or absent measures of clinical
synovitis or MSUS synovitis [22, 23]. Our study is the first
to our knowledge, which investigates the discordance of
elevated disease activity scores in obese patients and
absent/low measureable synovitis by PDUS.
The obese and overweight patients with RA pose a
considerable management challenge. Studies report that
obese and overweight patients with RA are less likely to
attain disease remission [24–26] and are more likely to
have limited therapeutic response [13] as compared to
non-obese RA patients, even with weight-adjusted treat-
ments [14]. Sandberg et al found a significant dose re-
sponse relationship between a BMI and change in
disease activity in a study of 495 Swedish patients. Those
with a BMI ≥ 25 had a 51% lower odds of reaching low
disease activity as measured by DAS28 after 6 months of
follow up (OR = 0.49 95%CI 0.31 to 0.78) [18]. Obese
RA patients also have higher rates of functional disabil-
ity, cardiovascular risks, and decreased quality of life as
compared to non-obese RA patients [27, 28]. Interestingly,
although overweight patients have a decreased chance of
achieving good disease control as measured by DAS28,
multiple studies have suggested that patients with higher
BMIs may have less radiographic joint damage [29], in
particular in ACPA positive obese patients [30]. Thus, the
natural question that arises is whether there could be
a potential measurement error of disease activity in
obese RA.
Our study implies that clinically assessed swollen
joints are less likely to represent true synovitis in obese
RA patients. Therefore, in obese patients, RA disease
activity can be overestimated by CDAI and DAS28
Table 2 Musculoskeletal ultrasound synovitis measures and disease activity measures, median IQR (25%, 75%)
Overall BMI <25 BMI 25–30 BMI >30 P-value
N = 43 N = 17 N = 12 N = 14
SJC 4 (3, 5) 5 (3, 5) 4 (2, 4.5) 4 (3, 5) 0.40
TJC 4 (2, 6) 4 (3, 6) 3 (2, 5) 4 (2, 6) 0.57
ESR 36.5 (25, 54) 37 (30, 54) 35 (24, 52) 40 (25, 54) 0.77
DAS28/ESR-4 6.3 (5.4, 6.9) 6.6 (5.4, 7.0) 6.2 (5.5, 6.5) 6.1 (5.2, 6.9) 0.44
CDAI 36 (26, 43) 36 (30, 44) 35 (21.5, 42) 35 (26, 42) 0.67
GSUS 5 (3, 6) 5 (3, 6) 4 (2.5, 6) 5.5 (4, 6) 0.42
PDUS 1 (0, 3) 3 (1, 4) 1 (0, 3.5) 0 (0, 2) 0.02
GSUS-Gray Scale Ultrasound, PDUS-Power doppler Ultrasound, SJC-Swollen Joint Count, TJC-Tender Joint Count, CDAI-Clinical Disease Activity Index, ESR-Erythrocyte
Sedimentation Rate. Kruskal-Wallis tests used to compare groups
Table 3 PDUS and Swollen Joint Agreement by BMI Group
Overall BMI < 25 BMI 25–30 BMI > 30 p
% Joints PDUS Positive 42% 54% 40% 30% 0.018
% Joints Swollen 44% 48% 37% 45% 0.611
% Agreement 66% 66% 66% 64% 0.713
Sensitivity 0.61 0.64 0.53 0.66 0.822
Specificity 0.68 0.70 0.74 0.64 0.691
PPV 0.59 0.71 0.58 0.44 0.023
NPV 0.71 0.62 0.71 0.81 0.084
PPV Positive Predictive Value, NPV Negative Predictive Value
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calculations which may help to explain the reports that
obese and overweight patients with RA are less likely to
attain remission and are more likely to have limited
therapeutic response as compared to non-obese RA
patients.
Multiple studies have reported that increased BMI is as-
sociated with less radiographic joint damage (total erosions,
joint space narrowing) in RA [29–31]. Theories to explain
this have invoked the protective effects of adipocytes on
synovial tissue, decreased hydroxypyridinium collagen
crosslinking, the anti-inflammatory properties of adiponec-
tin and estrogen [32] and beneficial bone remodeling
secondary to greater weight [29, 33]. Our study suggests
that obese RA patients may simply have less synovitis as
compared to non-obese patients with the same calculated
disease activity scores. This is an alternate possible explan-
ation for prior observations that obese patients who have a
less severe disease course radiographically as compared to
non-obese matched controls. The assumption that joint de-
struction in RA is related to synovial hyperemia is sup-
ported by several studies including a 2008 study by Naredo
et al which included MSUS with PDUS of 367 patients with
RA and demonstrated that PDUS signal was predicative of
radiographic erosions and progression on plain films
(R = 0.64) [34]. In addition, studies using bone marrow
edema as seen on magnetic resonance imaging (MRI) to
assess for disease activity have shown similar results. In a
2014 Baker et al study, a secondary analysis of the
GO-BEFORE and GO-FORWARD randomized clinical
trials, evaluated the efficacy of golimumab in combination
with methotrexate compared with methotrexate and
golimumab monotherapy and demonstrated that there
was a significantly negative correlation between bone
edema score and BMI at baseline [33].
Both ACR and EULAR support the use of MSUS to
monitor RA disease activity and this study suggests that
it may be a particularly important tool in the evaluation
and management of the obese patient. In the United
States 60–70% of RA patients are overweight or obese
[10, 11]. Therefore, assessment of PDUS could be con-
sidered in the majority of our RA patients in order to
gain a better understanding of their true disease activity.
Prior studies have suggested that MSUS with PDUS is
more sensitive than physical examination in detection of
synovitis [8] which is consistent with our study as obese
RA subjects with clinically swollen joints have a lower
PPV and a trend for higher NPV for true synovitis, while
the opposite is found for normal BMI patients.
Frequent MSUS assessments require an experienced
and consistent ultrasonographer and is a time consuming
process if a large number of joints are examined. Recent
studies have suggested that the addition of MSUS to man-
agement of an early RA patient population provides no
additional effect compared with a conventional tight
control strategy [35, 36]. However, if the correct estab-
lished RA patient population can be targeted, the costs
of MSUS may off set the burdens associated with
switching/escalating pharmacologic therapies including
support/authorization staff time, adverse events and side
effects of immunosuppressive medications. Our study
suggests that of all the joints included, the wrist,
MCP2 and MCP 3 show the greatest discrepancy in
swollen joint count by exam and PDUS activity
between patients with BMI > 30 and patients with
Fig. 1 The proportion of PDUS positivity stratified by BMI category and swollen joint status. PDUS: power Doppler ultrasound, BMI: body mass index
Table 4 Multivariate Logistic model for PDUS (accounts for
correlation among different joints in the same patient)
Odds Ratio 95% CI Lower 95% CI Upper P-value
Age 1.01 0.98 1.05 0.48
Sex (Female) 2.42 0.54 10.87 0.25
BMI (Ordinal) 0.52 0.30 0.93 0.03
Swollen (Yes) 2.50 1.40 4.48 0.01
PDUS power Doppler ultrasound
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BMI < 25. Further study could lead to the ability to
perform a more targeted exam.
This study is limited by a relatively small sample size,
however, several of our analyses included a larger number
of joint-specific pairwise agreement assessments between
swollen joint and PDUS. While the baseline patient char-
acteristics were similar across all BMI groups there were
no men in the BMI < 25 group. This was a cross-sectional
study and thus we are unable to examine the differential
effect, if any, on treatment response in patients who are
overweight or obese. Other patient co-morbidities such as
osteoarthritis and fibromyalgia were not obtained. Aside
from ESR and CRP we did not measure markers that
others have correlated with obese patients such as adipo-
nectin and leptin. We chose MSUS with PDUS as our
gold standard for synovitis while some may consider MRI
the gold standard. However, MRI is limited in the number
of joints that can be assessed and requires contrast and,
studies have demonstrated a high level of agreement
between MSUS with PDUS and MRI for detection of
synovitis [37, 38] with at least one study reporting that US
was more sensitive than MRI in the detection of synovitis
[39]. Additionally, as mentioned above, there is evidence
that obese patients have significantly less synovitis as mea-
sured by RA MRI (RAMRIS) synovitis score as compared
to patients with BMI <30 despite having similar disease
activity scores measured by DAS28(CRP) which is con-
sistent with our findings [33]. Lastly, we noted there
was a trivial difference in the depth from skin to joint
in the obese patients, but only at the wrist (0.1 mm),
versus those patients who were overweight or normal.
This difference was not significant enough to explain
lower scores (by way of beam penetration) in the obese
patients.
Conclusion
This study suggests that in a cohort of RA patients whose
rheumatologist was considering switching therapy, obese
RA subjects had lower PDUS scores than non-obese
patients while having similar clinical disease activity scores.
In addition, BMI ≥ 30 was an independent predictor of
lower PDUS while accounting for other factors. Obese RA
patients’ clinically swollen joints had a lower PPV and a
higher NPV for true synovitis. This implies that clinically
assessed swollen joints are less likely to represent true
synovitis in obese RA patients, suggesting that RA
disease activity can be overestimated by CDAI and
DAS28 calculations. With the push towards “treating to
target” of remission or low disease activity by DAS28 or
CDAI alone, the BMI of the patient should taken in to
account. If there is a question of whether a joint is
swollen, MSUS with PDUS could be considered prior
to changing or escalating therapy.
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